Antibodies conjugated to bioactive compounds can allow targeted delivery of therapeutics. Here the authors present a strategy for fusing nanobodies to suboptimal GPCR peptide ligands to potently and selectively activate receptors.
- Ross W. Cheloha
- Fabian A. Fischer
- Hidde L. Ploegh